---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-395517"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-09-18T20:05:31+00:00"
generated_at: "2026-09-18T20:06:07.741306+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Karyopharm issues $20M Series A convertible preferred stock to settle forbearance fees

## Summary
- Issued 20,000 shares of 0% Series A Convertible Perpetual Preferred, $1,000 liquidation preference each, on Sept 17, 2026.
- Convertible into common at $1.62/share; capped at 4,520,000 shares until stockholder consent, with cash settlement for excess.
- Preferred ranks senior to common; holders can force repurchase at $1,000 after Sept 17, 2029 or on fundamental changes.
- Company must seek stockholder approval by March 15, 2027; deferred cash settlement until then if conversion exceeds cap.

## SEC filing metadata
- accession: 0001193125-26-395517
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-09-18T20:05:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/0001193125-26-395517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/d141487d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-395517
- JSON: https://secwatch.observer/filing/0001193125-26-395517.json
- Plain text: https://secwatch.observer/filing/0001193125-26-395517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.